Pitfalls of treating chronic myeloid leukaemia with dasatinib – pulmonary arterial hypertension as a rare complication

Czech version

Authors: P. Čičátková; A. Kvetková; T. Horňák; L. Semerád; D. Žáčková
Authors‘ workplace: Interní hematologická a onkologická klinika, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno
Published in: Transfuze Hematol. dnes,1, 2020, No. Preview preliminary publication, p. 1-11.
Category:

Overview

Dasatinib is a potent tyrosine kinase inhibitor of not only Bcr-Abl1, but also of the Src kinase family, c-kit and PDGFR-β. This „off-target“ effect is the probable cause of pleural effusions, which complicate dasatinib therapy in about one third of patients. The following case report describes a chronic myeloid leukaemia patient with not only recurrent pleural effusions but also pulmonary arterial hypertension as a serious adverse event leading to dasatinib discontinuation.

Keywords:

chronic myeloid leukaemia – dasatinib – pleural effusions – pulmonary arterial hypertension

Sources

1. Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927.

2. Shah NP, Rouselot P, Schiffer Ch, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia patient: 7-years follow-up of study CA 180-034. Am J Hematol. 2016;91(9):869–874.

3. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effecctive in patients with Philaadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540–3546.

4. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-Näive chronic myeloid leukemia patients trial. J Clin Oncol.2016;34(20):2333–2340.

5. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia.2016;30(5):1044–1054.

6. Zackova D, Klamova H, Belohlavkova P, et al. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. Leuk Lymphoma. 2021;62(1):194–2020.

7. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem.2004;47:6658–6661.

8. O´Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistent Abl kinase domain mutants. Cancer Res.2005;65:450–4505.

9. Bergeon A, Rea D. Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia. Am J Respir Crit Care Med.2007;176:814–818.

10. Luton F, Verges M, Vaerman JP, et al. The SRC family protein tyosine kinase p62yes contols polymeric IgA transcytosis in vivo. Mol Cell.1999;4:627–632.

11. Quintás-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol.2007;25:3908–3914.

12. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol.2008;141:745–747.

13. Hellstom M, Kalen M, Lindahl P, et al. Role of PDGF-B and PDGFR- in recruitment of vascula smooth muscle cells and pericytes during embryonic blood vesel formation in the mouse. Development.1999;126:3047–3055.

14. La Rosée P, Martiat P, Leitner A, et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol.2013;92(10):1345–1350.

15. Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as fontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer.2020;126:67–75.

16. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia.2016;30:1648–1671.

17. Dodson MW, Brown LM, Elliot ChG. Pulmonary arterial hypertension. Heart Fail Clin.2018;14(3):255–269.

18. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood.2006;108(6):1809–1820.

19. Ryan JJ, Thenappan T, Luo N, et al. The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulm Circ.2012;2(1):107–121.

20. Čičátková P, Žáčková D. Vysazování inhibitorů tyrozinkináz u pacientů s chronickou myeloidní leukemií ve studiích a klinické praxi. Transfuze Hematol Dnes.2020;26(4):281–293.

Labels

Haematology Internal medicine Clinical oncology

A peripherally inserted central catheter is a safe means of ensuring long-term central venous access in patients with acute leukaemia – a single centre experience

POEMS syndrome – a rare disease associated with monoclonal gammopathy and polyneuropathy: diagnosis and treatment

Obinutuzumab in the treatment of a patient with Waldenström macroglobulinemia and rituximab intolerance: a case report

Article was published in

Transfusion and Haematology Today

2020 Issue Preview preliminary publication

Popular this week